Evommune EVMN
NYSE EVMN
$5.19 -0.19 (-3.53%)
As of: Oct 21, 2026 · 2:52 PM EDT

Evommune (EVMN) Current Deferred Revenue (2024)

Updated

Evommune (EVMN) reported Current Deferred Revenue of $3 million for Q4 2024.

Analysis

Evommune (EVMN) Current Deferred Revenue (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.71 Bn 1,105.29 Bn 19.71 Bn
2 Johnson & Johnson 617.55 Bn 536.07 Bn 17.26 Bn
3 AbbVie 501.02 Bn 474.13 Bn 12.70 Bn
4 Merck 368.18 Bn 322.56 Bn 12.21 Bn
5 Novartis Ag 297.89 Bn 261.88 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 236.60 Bn 191.99 Bn 7.24 Bn
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn
9 Pfizer 169.77 Bn 116.42 Bn 10.94 Bn
10 Evommune 188.27 Mn -449.25 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 3.00 Mn
API Access

Evommune Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=EVMN&period=max&api_key=YOUR_API_KEY